SWP
CRL icon

Stratos Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Stratos Wealth Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Sell
1,173
-9
-0.8% -$1.67K ﹤0.01% 1532
2025
Q4 		$236K Buy
+1,182
New +$214K ﹤0.01% 1427
2025
Q1 		– Sell
-1,523
Closed -$281K – 1392
2024
Q4 		$281K Sell
1,523
-314
-17% -$60.5K ﹤0.01% 1173
2024
Q3 		$362K Sell
1,837
-348
-16% -$72.3K 0.01% 1061
2024
Q2 		$451K Buy
2,185
+237
+12% +$53.7K 0.01% 939
2024
Q1 		$528K Sell
1,948
-479
-20% -$114K 0.01% 872
2023
Q4 		$574K Sell
2,427
-78
-3% -$15.3K 0.01% 825
2023
Q3 		$491K Buy
2,505
+493
+25% +$101K 0.01% 827
2023
Q2 		$423K Buy
2,012
+123
+7% +$24.5K 0.01% 833
2023
Q1 		$381K Sell
1,889
-240
-11% -$54.4K 0.01% 786
2022
Q4 		$464K Sell
2,129
-60
-3% -$13.1K 0.01% 756
2022
Q3 		$431K Sell
2,189
-152
-6% -$32.8K 0.01% 744
2022
Q2 		$501K Sell
2,341
-159
-6% -$38.9K 0.01% 732
2022
Q1 		$710K Buy
2,500
+175
+8% +$54K 0.02% 671
2021
Q4 		$876K Sell
2,325
-178
-7% -$69.2K 0.02% 594
2021
Q3 		$1.03M Buy
2,503
+355
+17% +$147K 0.03% 514
2021
Q2 		$795K Hold
2,148
– – 0.02% 621
2021
Q1 		$623K Buy
2,148
+108
+5% +$30K 0.02% 641
2020
Q4 		$510K Sell
2,040
-43
-2% -$10.2K 0.02% 673
2020
Q3 		$472K Sell
2,083
-40
-2% -$8.3K 0.02% 638
2020
Q2 		$370K Buy
2,123
+83
+4% +$13.2K 0.01% 703
2020
Q1 		$257K Hold
2,040
– – 0.01% 735
2019
Q4 		$312K Buy
2,040
+50
+3% +$6.92K 0.01% 736
2019
Q3 		$263K Hold
1,990
– – 0.01% 773
2019
Q2 		$282K Hold
1,990
– – 0.01% 755
2019
Q1 		$289K Hold
1,990
– – 0.01% 729
2018
Q4 		$225K Hold
1,990
– – 0.01% 763
2018
Q3 		$268K Buy
1,990
+190
+11% +$23.4K 0.01% 754
2018
Q2 		$202K Hold
1,800
– – 0.01% 899
2018
Q1 		$192K Sell
1,800
-11
-0.6% -$1.19K 0.01% 919
2017
Q4 		$198K Buy
+1,811
New +$197K 0.01% 881

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stratos Wealth Partners's CRL Position: Q1 2026 in Review

Stratos Wealth Partners reduced its Charles River Laboratories (CRL) stake by 0.76% in Q1 2026, selling an estimated $1.67K and leaving 1,173 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Stratos Wealth Partners first reported a position in CRL in Q4 2017 and has held it in 31 quarters since. The position peaked at $1.03M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Stratos Wealth Partners held 1,173 shares of Charles River Laboratories worth $202K as of Q1 2026.
  • Stratos Wealth Partners sold 9 Charles River Laboratories shares in Q1 2026, an estimated $1.67K.
  • Charles River Laboratories made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1532 holding.
  • Stratos Wealth Partners first reported a position in Charles River Laboratories in Q4 2017 and has held it in 31 quarters since.
  • Stratos Wealth Partners's Charles River Laboratories position peaked at $1.03M in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.